Cell/Gene Tx channel feed

Kym­ri­ah pi­o­neer Carl June is back, with first US hu­man ev­i­dence for CRISPR use in can­cer

6 years ago

MD An­der­son emerges with strong ev­i­dence for nat­ur­al killer cell ther­a­py, and Take­da looks like a win­ner

6 years ago
R&D

How much does it cost to boot­strap a gene ther­a­py start­up? Not too much if you're Jim Wil­son, per Pas­sage Bio's $125M IPO fil­ing

6 years ago
Financing

Catal­ent chief John Chimin­s­ki trig­gers a $315M-plus wa­ger on the boom­ing cell ther­a­py mar­ket now in the mak­ing

6 years ago
Deals
Outsourcing

Re­sis­tant to CAR-T ther­a­pies? It's the can­cer, not your im­mune sys­tem — study

6 years ago
R&D

Eye­ing a trio of tri­al ini­ti­a­tions, Jim Wilson's gene ther­a­py start­up woos Bruce Gold­smith from Deer­field as CEO

6 years ago
People

Deer­field vaults to the top of cell and gene ther­a­py CD­MO game with $1.1B fa­cil­i­ty at Philadel­phi­a's newest bio­phar­ma hub

6 years ago
Outsourcing

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

6 years ago
R&D
In Focus

With $110M to add to the bankroll, Gen­er­a­tion Bio sets its sights on en­gi­neer­ing a rev­o­lu­tion in the gene ther­a­py field

6 years ago
Financing

Chi­nese court sen­tences Jiankui He to 3 years in jail — and con­firms birth of 3rd CRISPR ba­by

6 years ago
China

Flag­ship bankrolls quest to cre­ate gene ther­a­py 2.0, with new vi­ral de­liv­ery tech in hand

6 years ago
Financing
Startups

In­side Astel­las' $3B Au­dentes gene ther­a­py ac­qui­si­tion: cod­ed mes­sages, a bid­ding war and $77M for the CEO

6 years ago
Deals

UK an­titrust watch­dog clears Roche/Spark deal — but what is the FTC think­ing?

6 years ago
Deals

Ju­ry finds Gilead li­able for $585M and big roy­al­ties in Kite CAR-T patent case

6 years ago

Kite Phar­ma's ex-CEO con­tra­dicts founder as CAR-T patent tri­al heats up, with con­flict­ing val­u­a­tions

6 years ago

Bris­tol-My­ers is mak­ing a bee-line to the FDA with pos­i­tive liso-cel da­ta — but is it too late in the CAR-T game?

6 years ago
R&D

Pa­tient #9 has been a con­cern, but Sang­amo and Pfiz­er are bull­ish about win­ning the marathon he­mo­phil­ia A gene ther­a­py race

6 years ago
R&D

J&J team shows off 'break­through' BC­MA CAR-T da­ta, and that could cause a big headache at blue­bird and Bris­tol-My­ers

6 years ago
R&D

With FDA re­view of its gene ther­a­py un­der­way, Fer­ring's $570M spin­out de­liv­ers in PhI­II blad­der can­cer read­out

6 years ago
R&D

No­var­tis, Ver­tex out­line big gene ther­a­py plans — fu­el­ing a glob­al boom

6 years ago

In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

6 years ago
R&D

Sarep­ta picks up a slate of pre­clin­i­cal gene ther­a­py pro­grams, seed­ing new Stride­Bio deal with $48M up­front

6 years ago
Deals

FDA puts Sol­id Bio’s lead gene ther­a­py pro­gram on hold — again — af­ter an­oth­er pa­tient is hurt by SGT-001

6 years ago
R&D

De­cry­ing 'ar­bi­trary and capri­cious' ac­tion, Re­genxBio sues FDA over clin­i­cal holds on gene ther­a­py

6 years ago
FDA+
First page Previous page 48495051525354 Next page Last page
A service from the Financial Times